Roche S Acquisition Of Genentech May 11 2015
Demetri Posey
Prof. Sanjay Jain
Monday, May 11 2015
Roche’s acquisition of Genentech
1. Roche is seeking to acquire the 44% of Genentech that it doesn’t own yet because it would create new opportunities for Roche and the ability to work together on a much broader scale. Also, Roche’s managers were highly aware that in 2015 their product licensing agreement with Genentech was going to expire. This agreement previously gave Roche the accessibility to many of Genentech’s new innovative products through research and development. If Roche were to acquire the rest of Genentech, there would be no blockage of information in R&D between the two companies, which could enhance innovative product development. On top of that many of Roche managers believed that the two companies spend a lot of the same efforts and have similar facilities, so an acquisition would cut cost and make operations more efficient. Finally, “in 2007, Genentech began to generate large amounts of free cash flow but with Roche’s current position they do not have access to the cash. However, if Roche and Genentech decided to merge and become one company than Roche would have unlimited access to Genentech’s cash. One of the risk associated with the potential acquisition was Genentech would loose some of their top scientists to fear that Genentech would lose its “independence and entrepreneurial spirit”. Also, the acquisition created a conflict of interest since Roche owed fiduciary duties to Genentech’s shareholders and the purchase could lead to potential lawsuits if it wasn’t handled correctly.
2. Genentech’s value as a stand-alone company using a weighted average cost of capital of 9% should range anywhere from $73.94 to $81.54 per share. Subtracting Genentech’s short and long-term debt and adding its cash accumulation and marketable securities and then finally dividing that number by the amount of shares outstanding can calculate Genentech’s stand-alone value.
3. In my opinion, I believe
Prof. Sanjay Jain
Monday, May 11 2015
Roche’s acquisition of Genentech
1. Roche is seeking to acquire the 44% of Genentech that it doesn’t own yet because it would create new opportunities for Roche and the ability to work together on a much broader scale. Also, Roche’s managers were highly aware that in 2015 their product licensing agreement with Genentech was going to expire. This agreement previously gave Roche the accessibility to many of Genentech’s new innovative products through research and development. If Roche were to acquire the rest of Genentech, there would be no blockage of information in R&D between the two companies, which could enhance innovative product development. On top of that many of Roche managers believed that the two companies spend a lot of the same efforts and have similar facilities, so an acquisition would cut cost and make operations more efficient. Finally, “in 2007, Genentech began to generate large amounts of free cash flow but with Roche’s current position they do not have access to the cash. However, if Roche and Genentech decided to merge and become one company than Roche would have unlimited access to Genentech’s cash. One of the risk associated with the potential acquisition was Genentech would loose some of their top scientists to fear that Genentech would lose its “independence and entrepreneurial spirit”. Also, the acquisition created a conflict of interest since Roche owed fiduciary duties to Genentech’s shareholders and the purchase could lead to potential lawsuits if it wasn’t handled correctly.
2. Genentech’s value as a stand-alone company using a weighted average cost of capital of 9% should range anywhere from $73.94 to $81.54 per share. Subtracting Genentech’s short and long-term debt and adding its cash accumulation and marketable securities and then finally dividing that number by the amount of shares outstanding can calculate Genentech’s stand-alone value.
3. In my opinion, I believe